Free lookups: 0/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
0 of 3 free lookups remaining Upgrade
New search Medicine profile Neomycin / Nystatin / Clobetasol

Clinical medicine profile

Neomycin / Nystatin / Clobetasol

HMG-CoA reductase inhibitor (statin)

POM
Evidence state Source-linked Review date not recorded
Route
ORAL
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • [From component Neomycin / Gramicidin / Nystatin / Triamcinolone Acetonide] Use on rosacea acne, peri-oral dermatitis, scabies, leg ulcers, tuberculous, untreated viral, bacterial or fungal infections, reaction to smallpox vaccination, first three months of pregnancy, continous prophylactic use.

Precautions

  • [From component Neomycin / Gramicidin / Nystatin / Triamcinolone Acetonide] Limit use in children or on face to maximum of 5 days.
  • It should be withdrawn gradually following prolonged therapy.
  • Unless fully unavoidable, potent corticosteroids should not be used on the face as they may precipitate a rosacea-like disorder and aggravate any pre-existing rosacea, avoid use in an occluded area, near the eye, use in the presence of skin infections without concomitant use of anti-microbial, children under 1yr, on weeping foci.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Directions Clean the affected area Apply a small amount of this product (an amount equal to the surface area of the tip of a finger) on the area 1 to 3 times daily May be covered with a sterile bandage.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

Some high-intensity agents need dose limits in severe CKD.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

Monitor LFTs as labelled; discontinue if persistent significant elevation.

03 Clinical use

Use, effects & interactions

Indications

  • Inflammation and infection of the skin particularly fungal and/or bacterial, contact eczema, atopic dermatitis, seborrheic dermatitis, mycotic eczema, microbial eczema, etc.
  • Clinical selection for Neomycin / Nystatin / Clobetasol should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: HMG-CoA reductase inhibitor (statin).
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • [From component Neomycin / Gramicidin / Nystatin / Triamcinolone Acetonide] Local irritation e.g burning sensation and itching, erythema rare, dryness of the skin, aggravation of concurrent untreated infections, thinning of the skin (this may be reversible), loss of skin elasticity, folliculitis, change in skin pigmentation, telangiectasia, purpura and steroid acne, increased growth of hair, severe pituitary-adrenal axis suppression and hypercotism, cushoid state, growth retardation, benign intra-cranial hypertension.
  • Fixed-dose/multi-ingredient product.
  • Clinical details partially inherited from component monographs: Neomycin / Gramicidin / Nystatin / Triamcinolone Acetonide, Nystatin, Clobetasol Dipropionate, skin.
  • Confirm combination SmPC for exact dosing.
04 Pharmacology

Mechanism & disposition

Combination product.

Inhibit HMG-CoA reductase↑ LDL receptors↓ LDL-C
Read complete mechanism

Combination product. Component mechanism (Neomycin / Gramicidin / Nystatin / Triamcinolone Acetonide): Combination product. Component mechanism (Nystatin): It has both fungicidal and fungi-static properties. It binds to sterols in the cell membrane of the fungus with a resultant change in membrane permeability, allowing leakage of intracellular components and causing cell death.

Onset

Lipid effects weeks

Duration

Chronic daily therapy

Route

ORAL

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[From component Neomycin / Gramicidin / Nystatin / Triamcinolone Acetonide] [From component Gramicidin] Pregnancy: Teratogenic Effects Adequate animal reproductive studies have not been conducted with neomycin, polymyxin B, or gramicidin. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only if clearly needed.

Lactation

[From component Neomycin / Gramicidin / Nystatin / Triamcinolone Acetonide] [From component Gramicidin] Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

06 Kenya market

Brands & loaded prices

From—
Median—
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; FDA drug label via OpenFDA/DailyMed; RxNorm (NLM RxNav); PubChem
Last reviewedNot recorded
EvidenceSource-linked
Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.